We are live on
!
Find out more
BC
Birchview Capital Portfolio holdings
AUM
$176M
1-Year Est. Return
95.04%
This Fund
S&P 500
This Quarter
Est. Return
-15.07%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$113M
AUM Growth
-$24.8M
(-18%)
Cap. Flow
+$8.66M
Cap. Flow
% of AUM
7.68%
Top 10 Holdings %
Top 10 Hldgs %
80.31%
Holding
57
New
5
Increased
11
Reduced
3
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Acadia Pharmaceuticals
ACAD
|
+$3.21M |
| 2 |
AMRN
Amarin Corp
AMRN
|
+$2.01M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$1.86M |
| 4 |
Biogen
BIIB
|
+$1.82M |
| 5 |
Gilead Sciences
GILD
|
+$1.38M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DERM
Dermira, Inc.
DERM
|
+$1.21M |
| 2 |
WMGI
Wright Medical Group Inc
WMGI
|
+$914K |
| 3 |
SLNO
Soleno Therapeutics
SLNO
|
+$877K |
| 4 |
Myriad Genetics
MYGN
|
+$817K |
| 5 |
Arvinas
ARVN
|
+$702K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.51% |
| 2 | Energy | 0.77% |
| 3 | Consumer Staples | 0.06% |
| 4 | Consumer Discretionary | 0.04% |
| 5 | Materials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Bristol-Myers Squibb
BMY
$124B
| $43.8M | 38.85% |
785,785
+7,200
| +0.9% | +$440K |
|
|
AXDX
2
DELISTED
Accelerate Diagnostics
AXDX
| $18.3M | 16.21% |
219,380
+1,000
| +0.5% | +$141K |
|
|
3
Neurocrine Biosciences
NBIX
$17.2B
| $6.41M | 5.68% |
74,000
+19,000
| +35% | +$1.86M |
|
4
QuidelOrtho
QDEL
$1.19B
| $4.78M | 4.24% |
48,844
| – | – |
|
|
5
Acadia Pharmaceuticals
ACAD
$4.38B
| $3.89M | 3.45% |
92,000
+78,000
| +557% | +$3.21M |
|
|
6
Biogen
BIIB
$30.4B
| $3.48M | 3.09% |
11,000
+6,000
| +120% | +$1.82M |
|
7
Karyopharm Therapeutics
KPTI
$216M
| $2.84M | 2.52% |
9,867
+4,534
| +85% | +$1.25M |
|
|
BMY.RT
8
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $2.69M | 2.38% |
706,848
+7,200
| +1% | +$23.7K |
|
|
VRML
9
DELISTED
Vermillion, Inc.
VRML
| $2.68M | 2.38% |
3,221,933
| – | – |
|
10
United Therapeutics
UTHR
$22.7B
| $1.71M | 1.51% |
18,000
+13,000
| +260% | +$1.24M |
|
|
XLRN
11
DELISTED
Acceleron Pharma
XLRN
| $1.68M | 1.49% |
18,672
| – | – |
|
|
OXFD
12
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $1.58M | 1.4% |
170,303
| – | – |
|
|
13
Gilead Sciences
GILD
$167B
| $1.5M | 1.33% |
+20,000
| New | +$1.38M |
|
|
CFRX
14
DELISTED
ContraFect Corporation
CFRX
| $1.47M | 1.31% |
3,196
-338
| -10% | -$231K |
|
|
MASI
15
DELISTED
Masimo
MASI
| $1.42M | 1.26% |
8,000
| – | – |
|
|
CCXI
16
DELISTED
ChemoCentryx, Inc.
CCXI
| $1.21M | 1.07% |
30,000
+5,000
| +20% | +$212K |
|
|
EPZM
17
DELISTED
Epizyme, Inc
EPZM
| $931K | 0.83% |
+60,000
| New | +$1.29M |
|
|
ARNA
18
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $924K | 0.82% |
22,000
| – | – |
|
19
Vanda Pharmaceuticals
VNDA
$327M
| $829K | 0.74% |
80,000
| – | – |
|
|
ALBO
20
DELISTED
Albireo Pharma Inc
ALBO
| $786K | 0.7% |
48,000
| – | – |
|
|
AMRN
21
Amarin Corp
AMRN
$292M
| $720K | 0.64% |
9,000
+6,050
| +205% | +$2.01M |
|
22
Harrow
HROW
$1.74B
| $688K | 0.61% |
180,000
| – | – |
|
|
IMGN
23
DELISTED
Immunogen Inc
IMGN
| $648K | 0.57% |
190,000
+10,000
| +6% | +$43.7K |
|
|
EQM
24
DELISTED
EQM Midstream Partners, LP
EQM
| $605K | 0.54% |
51,250
| – | – |
|
|
25
Arvinas
ARVN
$517M
| $604K | 0.54% |
15,000
-15,000
| -50% | -$702K |
|
Similar funds
RWA
BAM
TIM
TFCM
FPW
LWM
PFA
DAM
Birchview Capital's Q1 2020 Portfolio in Review
As of Q1 2020, Birchview Capital held 57 positions worth $113M, down 18% from $138M the previous quarter. Its ten largest holdings account for 80% of the portfolio.
Birchview Capital deployed $8.66M of net new capital in Q1 2020, opening 5 new positions and adding to 11 existing holdings. Its largest new stake was Gilead Sciences: 20,000 shares worth $1.5M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 95% a quarter earlier, followed by Energy and Consumer Staples.
On the sell side, the largest reduction was Soleno Therapeutics, an estimated $877K trimmed.
- Birchview Capital's largest Q1 2020 buy was Gilead Sciences: 20,000 shares worth $1.5M.
- Birchview Capital added most to Acadia Pharmaceuticals in Q1 2020, an estimated $3.21M increase.
- Birchview Capital's biggest Q1 2020 reduction was Soleno Therapeutics, cutting an estimated $877K.
- Birchview Capital fully exited Dermira, Inc. in Q1 2020, selling an estimated $1.21M.
- Birchview Capital's ten largest holdings make up 80% of its $113M portfolio in Q1 2020.
- Birchview Capital opened 5 new positions and closed 11 in Q1 2020.
- Birchview Capital's portfolio value fell 18% quarter-over-quarter to $113M.
Based on Birchview Capital's 13F filing for Q1 2020, filed 12 May 2020.